59 msfocusmagazine.org B-cells. (Among other functions, B-cells activate the T-cells that cause damage to myelin). In a phase II trial, significantly fewer T1 Gd-enhancing lesions, total number of T1 Gd-enhancing lesions, and new or enlarging T2 lesions were observed with ofatumumab compared with placebo. No unexpected safety signals emerged in this study. Infusion- related reactions were common on infusion Day 1, but not observed on infusion Day 2. Neither the phase II MIRROR, trial, nor the phase III ASCLEPIOS trials have reported results. Masitinib is an orally-administered tyrosine kinase inhibitor that targets mast cells and inhibits several biochemical processes. This DMT is being studied in patients with both primary-progressive and secondary-progressive MS. In one early study, masitinib appeared to have a positive effect on MS-related impairment in patients with primary-progressive and relapse-free secondary-progressiveMS.Themostcommonly reported adverse events were weakness, rash, nausea, edema, and diarrhea. A phase III trial in patients with either primary-progressive or relapse-free secondary-progressive MS has not reported results.